X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/novartis-dials-2024-sales-outlook-preps-key-expansions-3-cancer-drugs
https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-tentative-usfda-nod-for-breast-cancer-drug/articleshow/108939360.cms
https://www.globenewswire.com//news-release/2023/12/08/2793232/0/en/Latest-Novartis-Kisqali-NATALEE-analysis-reinforces-25-reduction-in-risk-of-recurrence-across-broad-population-of-patients-with-early-breast-cancer-supports-regulatory-submissions.html
https://www.globenewswire.com/news-release/2023/12/05/2791260/0/en/Olema-Oncology-Announces-Palazestrant-Demonstrates-Attractive-Combinability-with-CDK4-6-Inhibitors-Ribociclib-and-Palbociclib-in-Phase-1b-2-Studies.html
https://www.fiercepharma.com/pharma/novartis-dials-midterm-sales-projection-fleshes-out-kisqalis-7b-plus-goal
https://www.globenewswire.com/news-release/2023/11/20/2782908/0/en/Novartis-showcases-significant-data-updates-from-Kisqali-iptacopan-and-Scemblix-at-SABCS-and-ASH.html
https://www.globenewswire.com//news-release/2023/10/20/2763906/0/en/Novartis-Kisqali-NATALEE-analysis-reinforces-consistent-reduction-in-risk-of-recurrence-across-key-subgroups-of-patients-with-early-breast-cancer.html
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-drug-cuts-recurrence-risk-by-25-early-stage-breast-cancer-2023-06-02/
https://www.globenewswire.com/news-release/2023/05/30/2678864/0/en/Olema-Oncology-to-Present-at-the-2023-Jefferies-Healthcare-Conference.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215976
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215975
https://www.globenewswire.com/news-release/2023/04/26/2655324/0/en/Novartis-to-present-new-data-across-oncology-portfolio-including-Kisqali-Phase-III-NATALEE-trial-in-early-breast-cancer-at-ASCO.html
https://www.fiercepharma.com/pharma/amid-novartis-rd-cull-kisqali-and-pluvicto-expansions-occupy-investors-mind
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-says-kisqali-breast-cancer-drug-cuts-risk-recurrence-2023-03-27/
https://www.globenewswire.com/news-release/2023/03/27/2634854/0/en/NATALEE-TRIO033-Phase-III-trial-demonstrates-ribociclib-significantly-reduces-the-risk-of-recurrence-for-patients-with-early-breast-cancer-at-interim-analysis.html
https://www.prnewswire.com/news-releases/novartis-kisqali-prolonged-pfs-benefit-for-pre--and-perimenopausal-patients-with-aggressive-hrher2-metastatic-breast-cancer-compared-to-chemotherapy-301696189.html
https://www.fiercepharma.com/pharma/among-novartis-key-growth-drivers-ms-drug-kesimpta-surges-kisqali-sees-positive-trend-breast
https://www.europeanpharmaceuticalreview.com/news/169184/kisqali-longest-median-os-breast-cancer/
https://www.fiercepharma.com/pharma/novartis-determined-to-dethrone-pfizer-to-launch-bold-kisqali-ibrance-head-to-head-trial
https://www.onclive.com/view/ribociclib-endocrine-therapy-improves-os-regardless-of-age-in-advanced-hr-her2--breast-cancer
https://www.biospace.com/article/releases/novartis-kisqali-and-174-ribociclib-product-monograph-in-canada-now-includes-monaleesa-3-data-demonstrating-statistically-significant-improvement-in-overall-survival-in-postmenopausal-women-with-hr-her2-advanced-breast-cancer/
https://www.prnewswire.com/news-releases/novartis-kisqali-demonstrates-nearly-five-years-median-overall-survival-in-metastatic-breast-cancer-301188951.html
https://www.newswire.ca/news-releases/novartis-monaleesa-7-kisqali-r-ribociclib-study-demonstrated-statistically-significant-improvement-in-overall-survival-in-pre-and-perimenopausal-women-with-hr-her2-advanced-breast-cancer-853626815.html
https://www.globenewswire.com/news-release/2020/05/27/2039066/0/en/Novartis-announces-new-late-breaking-ofatumumab-data-at-EAN-demonstrating-robust-efficacy-and-safety-in-the-treatment-of-relapsing-forms-of-multiple-sclerosis-RMS.html
https://www.prnewswire.com/news-releases/alliancerx-walgreens-prime-studies-the-use-of-cyclin-dependent-kinase-46-inhibitors-in-breast-cancer-patients-301056092.html
https://www.fiercepharma.com/marketing/novartis-debuts-first-tv-ad-kisqali-campaign-for-mbc-treatment-touts-latest-study-results
http://www.pharmatimes.com/news/novartis_kisquali_bests_az_faslodex_in_breast_cancer_trial_1319827
https://endpts.com/novartis-eli-lilly-marquee-positive-survival-data-for-cdk-4-6-franchises-but-can-they-actually-beat-pfizers-blockbuster/
https://www.cancertherapyadvisor.com/home/cancer-topics/breast-cancer/fda-warns-of-possible-interstitial-lung-disease-pneumonitis-with-certain-breast-cancer-drugs/
https://www.raps.org/news-and-articles/news-articles/2019/9/three-breast-cancer-drugs-fda-warns-of-rare-but-s
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer
http://www.pharmatimes.com/news/nice_u-turn_for_kisquali_in_breast_cancer_1294696
https://www.fiercepharma.com/marketing/novartis-kisqali-trailing-lilly-s-verzenio-nabs-restricted-nice-backing-breast-cancer
https://www.fiercebiotech.com/biotech/u-k-drug-discovery-startup-healx-taps-gsk-astex-alum-as-cso
http://www.pharmatimes.com/news/novartis_kisqali_hits_endpoints_in_phase_iii_breast_cancer_trial_1289673
https://www.fiercepharma.com/pharma/asco-2019-what-to-watch-for-including-keytruda-lynparza-seagen-and-more
https://www.fiercepharma.com/manufacturing/novartis-sees-saudi-arabia-as-promising-market-for-producing-its-cancer-drugs
https://www.fiercepharma.com/pharma/novartis-kisqali-takes-step-back-heated-market-after-nice-no-vote
http://www.pharmatimes.com/news/novartis_kisqali_hit_with_nice_rejection_1284180
http://www.pmlive.com/pharma_news/nice_nod_for_lillys_breast_cancer_drug_verzenio_via_cdf_1283145
http://www.pmlive.com/pharma_news/nice_nod_for_lillys_breast_cancer_drug_verzenio_via_cdf_1283145
http://www.pharmafile.com/news/519113/nice-rejects-elil-lillys-verzenio-breast-cancer-draft-guidance
http://www.pmlive.com/pharma_news/lilly_gets_ema_nod_for_verzenio_in_breast_cancer_1254352
http://www.pmlive.com/pharma_news/novartis_considers_filings_for_pi3k_drug_in_breast_cancer_1249957
https://endpts.com/fda-gives-merck-real-time-review-for-keytruda-offering-a-peak-at-the-latest-extension-of-the-agencys-data-express-highway/?utm_medium=email&utm_campaign=Tuesday%20August%2021%202018&utm_content=Tuesday%20August%2021%202018+CID_191f277ba046b11178557c1a8f8234b2&utm_source=ENDPOINTS%20emails&utm_term=FDA%20gives%20Merck%20real-time%20review%20for%20Keytruda%20offering%20a%20peek%20at%20the%20latest%20extension%20of%20the%20agencys%20data%20express%20highway
https://www.fiercepharma.com/pharma/under-fda-pilot-merck-s-keytruda-scores-paramount-approval-lung-cancer
Market Place
Share 
